{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:52:54Z","timestamp":1771491174127,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:00:00Z","timestamp":1611964800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:00:00Z","timestamp":1611964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11033-021-06173-8","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T05:02:35Z","timestamp":1611982955000},"page":"1335-1343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Regulation of valproic acid induced EMT by AKT\/GSK3\u03b2\/\u03b2-catenin signaling pathway in triple negative breast cancer"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8415-6883","authenticated-orcid":false,"given":"Zeynep","family":"Ozman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3355-7801","authenticated-orcid":false,"given":"Betul","family":"Ozbek Iptec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvan","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-9914","authenticated-orcid":false,"given":"Gamze","family":"Guney Eskiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-4279","authenticated-orcid":false,"given":"Asuman","family":"Deveci Ozkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6043-2521","authenticated-orcid":false,"given":"Suleyman","family":"Kaleli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,30]]},"reference":[{"key":"6173_CR1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4161\/epi.3.3.6253","volume":"3","author":"S Marsoni","year":"2008","unstructured":"Marsoni S, Damia G, Camboni G (2008) A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics 3:164\u2013171 https:\/\/doi.org\/10.4161\/epi.3.3.6253","journal-title":"Epigenetics"},{"key":"6173_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejphar.2018.07.057","volume":"835","author":"H Heers","year":"2018","unstructured":"Heers H, Stanislaw J, Harrelson J, Lee MW (2018) Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer. Eur J Pharmacol 835:61\u201374 https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.057","journal-title":"Eur J Pharmacol"},{"key":"6173_CR3","doi-asserted-by":"publisher","first-page":"a026831","DOI":"10.1101\/cshperspect.a026831","volume":"6","author":"Y Li","year":"2016","unstructured":"Li Y, Seto E (2016) HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 6:a026831 https:\/\/doi.org\/10.1101\/cshperspect.a026831","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"6173_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2174\/1389557515666150521162237","volume":"15","author":"J Behera","year":"2015","unstructured":"Behera J, Jayaprakash V, Sinha BN (2015) Histone deacetylase inhibitors: a review on class-I specific inhibition. Mini Rev Med Chem 15(9):731\u2013750 https:\/\/doi.org\/10.2174\/1389557515666150521162237","journal-title":"Mini Rev Med Chem"},{"key":"6173_CR5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fonc.2018.00092","volume":"8","author":"A Suraweera","year":"2018","unstructured":"Suraweera A, O'Byrne KJ, Richard DJ (2018) Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol 8:92 https:\/\/doi.org\/10.3389\/fonc.2018.00092","journal-title":"Front Oncol"},{"issue":"3","key":"6173_CR6","first-page":"816","volume":"17","author":"MH Fang","year":"2009","unstructured":"Fang MH, Ji XM (2009) Histone modification and its application in therapy for hematologic malignancies. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17(3):816\u2013820","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"46","key":"6173_CR7","doi-asserted-by":"publisher","first-page":"20003","DOI":"10.1073\/pnas.1013754107","volume":"107","author":"M Namdar","year":"2010","unstructured":"Namdar M, Perez G, Ngo L, Marks PA (2010) Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A 107(46):20003\u201320008 https:\/\/doi.org\/10.1073\/pnas.1013754107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"6173_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00228-018-2444-2","volume":"74","author":"C Rodrigues","year":"2018","unstructured":"Rodrigues C, Chhun S, Chiron C, Dulac O, Rey E, Pons G, Jullien V (2018) A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy. Eur J Clin Pharmacol 74(6):793\u2013803. https:\/\/doi.org\/10.1007\/s00228-018-2444-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"6173_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2217\/epi-2016-0034","volume":"8","author":"S Khan","year":"2016","unstructured":"Khan S, Ahirwar K, Jena G (2016) Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms. Epigenomics 8(8):1087\u20131101 https:\/\/doi.org\/10.2217\/epi-2016-0034","journal-title":"Epigenomics"},{"issue":"12","key":"6173_CR10","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-17-0074","volume":"16","author":"LNK Tran","year":"2017","unstructured":"Tran LNK, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, Michael MZ, Lower KM, Sykes PJ (2017) The combination of metformin and valproic acid induces synergistic apoptosis in the presence of p53 and androgen signaling in prostate cancer. Mol Cancer Ther 16(12):2689\u20132700 https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0074","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"6173_CR11","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M G\u00f6ttlicher","year":"2001","unstructured":"G\u00f6ttlicher M, Minucci S, Zhu P, Kr\u00e4mer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969\u20136978 https:\/\/doi.org\/10.1093\/emboj\/20.24.6969","journal-title":"EMBO J"},{"issue":"4","key":"6173_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2174\/156800912800190884","volume":"12","author":"N Tinari","year":"2012","unstructured":"Tinari N, De Tursi M, Grassadonia A, Zilli M, Stuppia L, Iacobelli S, Natoli C (2012) An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets 12(4):439\u2013452 https:\/\/doi.org\/10.2174\/156800912800190884","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"6173_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.biocel.2008.08.019","volume":"41","author":"L Travaglini","year":"2009","unstructured":"Travaglini L, Vian L, Billi M, Grignani F, Nervi C (2009) Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 41(1):225\u2013234 https:\/\/doi.org\/10.1016\/j.biocel.2008.08.019","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"6173_CR14","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.3892\/ijo.2015.3213","volume":"47","author":"T Mawatari","year":"2015","unstructured":"Mawatari T, Ninomiya I, Inokuchi M, Harada S, Hayashi H, Oyama K, Makino I, Nakagawara H, Miyashita T, Tajima H, Takamura H, Fushida S, Ohta T (2015) Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation. Int J Oncol 47(6):2073\u20132081 https:\/\/doi.org\/10.3892\/ijo.2015.3213","journal-title":"Int J Oncol"},{"key":"6173_CR15","doi-asserted-by":"publisher","first-page":"19341","DOI":"10.1038\/srep19341","volume":"6","author":"MG Kelkar","year":"2016","unstructured":"Kelkar MG, Senthilkumar K, Jadhav S, Gupta S, Ahn BC, De A (2016) Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation. Sci Rep 6:19341 https:\/\/doi.org\/10.1038\/srep19341","journal-title":"Sci Rep"},{"issue":"6","key":"6173_CR16","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1172\/JCI39675","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119(6):1417\u20131419 https:\/\/doi.org\/10.1172\/JCI39675","journal-title":"J Clin Invest"},{"issue":"2","key":"6173_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10911-010-9178-9","volume":"15","author":"DS Micalizzi","year":"2010","unstructured":"Micalizzi DS, Farabaugh SM, Ford HL (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15(2):117\u2013134 https:\/\/doi.org\/10.1007\/s10911-010-9178-9","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"3","key":"6173_CR18","doi-asserted-by":"publisher","first-page":"e58672","DOI":"10.1371\/journal.pone.0058672","volume":"8","author":"FS Giudice","year":"2013","unstructured":"Giudice FS, Pinto DS Jr, N\u00f6r JE, Squarize CH, Castilho RM (2013) Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One 8(3):e58672 https:\/\/doi.org\/10.1371\/journal.pone.0058672","journal-title":"PLoS One"},{"issue":"3","key":"6173_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12272-015-0567-x","volume":"38","author":"YH Cha","year":"2015","unstructured":"Cha YH, Yook JI, Kim HS, Kim NH (2015) Catabolic metabolism during cancer EMT. Arch Pharm Res 38(3):313\u2013320 https:\/\/doi.org\/10.1007\/s12272-015-0567-x","journal-title":"Arch Pharm Res"},{"key":"6173_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.biopha.2016.10.023","volume":"84","author":"L Wu","year":"2016","unstructured":"Wu L, Feng H, Hu J, Tian X, Zhang C (2016) Valproic acid (VPA) promotes the epithelial mesenchymal transition of hepatocarcinoma cells via transcriptional and post-transcriptional up regulation of snail. Biomed Pharmacother 84:1029\u20131035 https:\/\/doi.org\/10.1016\/j.biopha.2016.10.023","journal-title":"Biomed Pharmacother"},{"key":"6173_CR21","doi-asserted-by":"publisher","first-page":"610495","DOI":"10.1155\/2014\/610495","volume":"2014","author":"LA Marquez-Curtis","year":"2014","unstructured":"Marquez-Curtis LA, Qiu Y, Xu A, Janowska-Wieczorek A (2014) Migration, proliferation, and differentiation of cord blood mesenchymal stromal cells treated with histone deacetylase inhibitor valproic acid. Stem Cells Int 2014:610495 https:\/\/doi.org\/10.1155\/2014\/610495","journal-title":"Stem Cells Int"},{"key":"6173_CR22","doi-asserted-by":"publisher","first-page":"172745","DOI":"10.1016\/j.ejphar.2019.172745","volume":"865","author":"S Zhang","year":"2019","unstructured":"Zhang S, Tang Z, Qing B, Tang R, Duan Q, Ding S, Deng D (2019) Valproic acid promotes the epithelial-to-mesenchymal transition of breast cancer cells through stabilization of snail and transcriptional upregulation of Zeb1. Eur J Pharmacol 865:172745 https:\/\/doi.org\/10.1016\/j.ejphar.2019.172745","journal-title":"Eur J Pharmacol"},{"issue":"7664","key":"6173_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD et al (2017) Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547(7664):453\u2013457 https:\/\/doi.org\/10.1038\/nature23007","journal-title":"Nature"},{"issue":"12","key":"6173_CR24","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/j.ejca.2013.03.014","volume":"49","author":"H Zheng","year":"2013","unstructured":"Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T, Shi M, Wang Z, Jiang B (2013) Glycogen synthase kinase-3 beta regulates snail and \u03b2-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer 49(12):2734\u20132746 https:\/\/doi.org\/10.1016\/j.ejca.2013.03.014","journal-title":"Eur J Cancer"},{"issue":"4","key":"6173_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/19336918.2015.1016686","volume":"9","author":"W Xu","year":"2015","unstructured":"Xu W, Yang Z, Lu N (2015) A new role for the PI3K\/Akt signaling pathway in the epithelial-mesenchymal transition. Cell Adhes Migr 9(4):317\u2013324 https:\/\/doi.org\/10.1080\/19336918.2015.1016686","journal-title":"Cell Adhes Migr"},{"issue":"6","key":"6173_CR26","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","volume":"149","author":"H Clevers","year":"2012","unstructured":"Clevers H, Nusse R (2012) Wnt\/\u03b2-catenin signaling and disease. Cell 149(6):1192\u20131205 https:\/\/doi.org\/10.1016\/j.cell.2012.05.012","journal-title":"Cell"},{"issue":"5","key":"6173_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3325\/cmj.2017.58.349","volume":"58","author":"XJ Ma","year":"2017","unstructured":"Ma XJ, Wang YS, Gu WP, Zhao X (2017) The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells. Croat Med J 58(5):349\u2013357 https:\/\/doi.org\/10.3325\/cmj.2017.58.349","journal-title":"Croat Med J"},{"issue":"1\u20132","key":"6173_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11010-011-1085-x","volume":"361","author":"L Zhang","year":"2012","unstructured":"Zhang L, Wang G, Wang L, Song C, Leng Y, Wang X, Kang J (2012) VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Mol Cell Biochem 361(1\u20132):39\u201345 https:\/\/doi.org\/10.1007\/s11010-011-1085-x","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"6173_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","volume":"10","author":"SG Pai","year":"2017","unstructured":"Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ (2017) Wnt\/beta-catenin pathway: modulating anticancer immune response. J Hematol Oncol 10(1):101 https:\/\/doi.org\/10.1186\/s13045-017-0471-6","journal-title":"J Hematol Oncol"},{"issue":"7774","key":"6173_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41586-019-1526-3","volume":"573","author":"V Padmanaban","year":"2019","unstructured":"Padmanaban V, Krol I, Suhail Y, Szczerba BM, Aceto N, Bader JS, Ewald AJ (2019) E-cadherin is required for metastasis in multiple models of breast cancer. Nature 573(7774):439\u2013444 https:\/\/doi.org\/10.1038\/s41586-019-1526-3","journal-title":"Nature"},{"issue":"20","key":"6173_CR31","doi-asserted-by":"publisher","first-page":"33972","DOI":"10.18632\/oncotarget.15687","volume":"8","author":"S Shang","year":"2017","unstructured":"Shang S, Hua F, Hu ZW (2017) The regulation of \u03b2-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8(20):33972\u201333989 https:\/\/doi.org\/10.18632\/oncotarget.15687","journal-title":"Oncotarget"},{"key":"6173_CR32","doi-asserted-by":"publisher","unstructured":"Huels DJ, Ridgway RA, Radulescu S, Leushacke M, Campbell AD, Biswas S et al (2015) E-cadherin can limit the transforming properties of activating \u03b2-catenin mutations. EMBO J 14;34(18):2321\u20132333 https:\/\/doi.org\/10.15252\/embj.201591739","DOI":"10.15252\/embj.201591739"},{"key":"6173_CR33","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/s12276-020-0440-y","volume":"52","author":"WJ Ryu","year":"2020","unstructured":"Ryu WJ, Lee JD, Park JC, Cha PH, Cho YH, Kim JY, Sohn JH, Paik S, Choi KY (2020) Destabilization of \u03b2-catenin and RAS by targeting the Wnt\/\u03b2-catenin pathway as a potential treatment for triple-negative breast cancer. Exp Mol Med 52:832\u2013842 https:\/\/doi.org\/10.1038\/s12276-020-0440-y","journal-title":"Exp Mol Med"},{"issue":"5","key":"6173_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/ajcp\/aqw183","volume":"146","author":"T Shen","year":"2016","unstructured":"Shen T, Zhang K, Siegal GP, Wei S (2016) Prognostic value of E-cadherin and \u03b2-catenin in triple-negative breast cancer. Am J Clin Pathol 146(5):603\u2013610. https:\/\/doi.org\/10.1093\/ajcp\/aqw183","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"6173_CR35","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.ajpath.2018.05.003","volume":"188","author":"N Borcherding","year":"2018","unstructured":"Borcherding N, Cole K, Kluz P, Jorgensen M, Kolb R, Bellizzi A, Zhang W (2018) Re-evaluating E-cadherin and \u03b2-catenin: a pan-cancer proteomic approach with an emphasis on breast cancer. Am J Pathol 188(8):1910\u20131920. https:\/\/doi.org\/10.1016\/j.ajpath.2018.05.003","journal-title":"Am J Pathol"},{"issue":"6","key":"6173_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","volume":"79","author":"M Song","year":"2019","unstructured":"Song M, Bode AM, Dong Z, Lee MH (2019) AKT as a therapeutic target for cancer. Cancer Res 79(6):1019\u20131031 https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2738","journal-title":"Cancer Res"},{"issue":"5","key":"6173_CR37","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/cells9051110","volume":"9","author":"P Duda","year":"2020","unstructured":"Duda P, Akula SM, Abrams SL, Steelman LS, Martelli AM, Cocco L et al (2020) Targeting GSK3 and associated signaling pathways involved in cancer. Cells 9(5):1110 https:\/\/doi.org\/10.3390\/cells9051110","journal-title":"Cells"},{"issue":"3","key":"6173_CR38","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.3892\/ol.2016.4880","volume":"12","author":"Q Xia","year":"2016","unstructured":"Xia Q, Zheng Y, Jiang W, Huang Z, Wang M, Rodriguez R, Jin X (2016) Valproic acid induces autophagy by suppressing the Akt\/mTOR pathway in human prostate cancer cells. Oncol Lett 12(3):1826\u20131832 https:\/\/doi.org\/10.3892\/ol.2016.4880","journal-title":"Oncol Lett"},{"key":"6173_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/1471-2407-14-370","volume":"14","author":"P Shi","year":"2014","unstructured":"Shi P, Yin T, Zhou F, Cui P, Gou S, Wang C (2014) Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K\/Akt signaling pathway. BMC Cancer 14:370 https:\/\/doi.org\/10.1186\/1471-2407-14-370","journal-title":"BMC Cancer"},{"issue":"6","key":"6173_CR40","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1159\/000447912","volume":"39","author":"C Zhang","year":"2016","unstructured":"Zhang C, Liu S, Yuan X, Hu Z, Li H, Wu M, Yuan J, Zhao Z, Su J, Wang X, Liao Y, Liu Q (2016) Valproic acid promotes human glioma U87 cells apoptosis and inhibits glycogen synthase kinase-3\u03b2 through ERK\/Akt signaling. Cell Physiol Biochem 39(6):2173\u20132185 https:\/\/doi.org\/10.1159\/000447912","journal-title":"Cell Physiol Biochem"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06173-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11033-021-06173-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-06173-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T16:16:05Z","timestamp":1614701765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-021-06173-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["6173"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-06173-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,30]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts and financial of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethics approval was received for conducting this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}